Drink glucose and your pancreas releases more insulin than it does when the same glucose is infused into a vein to reproduce a similar blood-glucose curve: the glucose concentration is comparable, yet the insulin response is not.
That difference is the incretin effect. It shows that your body reads a meal through more than the glucose concentration in your bloodstream. Nutrients in the gastrointestinal tract activate hormone signals. Those signals help coordinate insulin secretion, glucagon, and gastric emptying. They help coordinate appetite and nutrient handling. They help coordinate communication among the gut, pancreas, liver, and brain.
The two best-established incretin hormones are glucose-dependent insulinotropic polypeptide, abbreviated GIP, and glucagon-like peptide 1, abbreviated GLP-1. Both increase insulin secretion when glucose is elevated. They overlap, but they are not interchangeable, and their biology is more complex than a label such as “natural insulin boosters” suggests.
The experiment that defines the effect#
The cleanest demonstration uses two study visits.
On one visit, a participant drinks glucose. Investigators measure blood glucose, insulin, and often C-peptide over time. On another visit, glucose is delivered intravenously. The infusion rate is adjusted so that the blood-glucose curve resembles the curve from the oral visit. This is called an isoglycemic intravenous glucose infusion.
If circulating glucose alone determined insulin secretion, the insulin responses would be similar. Instead, oral glucose usually produces substantially more insulin secretion in people with normal glucose regulation. Reviews commonly estimate that gut-derived signals account for roughly half or more of the insulin released after oral glucose, although the exact proportion depends on the dose, protocol, population, assay, and calculation.
The comparison is important. Simply finding that insulin rises after a meal would not isolate the gut signal, because glucose itself stimulates beta cells. Matching the glucose curves asks a sharper causal question: what does the oral route add when the principal circulating stimulus is held approximately comparable?
The match is never perfect. Portal-vein glucose, neural signals, gastric emptying, nutrient contact, and the timing of hormone release differ between routes, and those differences are part of the meal response rather than reasons to dismiss it. The design operationalizes the effect; it does not reduce all post-meal physiology to two peptides.
Where GIP and GLP-1 come from#
GIP is released mainly from enteroendocrine K cells, which are abundant in the duodenum and proximal small intestine. GLP-1 is produced from the proglucagon gene in enteroendocrine L cells, with many L cells in the distal small intestine and colon. The older picture of sharply separated cell populations is too simple: cell types and hormone expression overlap across the intestine.
Carbohydrate, fat, and protein can stimulate these cells through nutrient transporters and receptors. They act through electrical activity, neural pathways, and signals from nearby cells. Hormone release begins rapidly, sometimes before much nutrient reaches the distal bowel; that speed reflects proximal cells, neural and endocrine relay mechanisms, and the fact that L cells also exist more proximally than a textbook map may imply.
After release, active GIP and GLP-1 have short lives. The enzyme dipeptidyl peptidase 4, or DPP-4, cleaves both rapidly. The kidneys and other tissues also contribute to clearance. Only a fraction of newly secreted active hormone reaches the systemic circulation intact.
Short survival is not a design flaw. It allows meal-linked signals to turn on and off quickly. It also explains two therapeutic strategies: DPP-4 inhibitors prolong endogenous incretin activity, while receptor agonists are engineered to resist rapid degradation and produce longer receptor signaling.
What “glucose-dependent” means#
GIP and GLP-1 enhance insulin secretion most when glucose is elevated. As glucose falls, their insulinotropic effect diminishes. This glucose dependence helps explain why an incretin pathway does not behave like a fixed dose of externally supplied insulin.
The phrase still needs care. It does not mean that every medicine acting on an incretin pathway has no hypoglycemia risk. Risk depends on your whole regimen and clinical context. Combining an incretin-based medicine with insulin or a sulfonylurea can increase hypoglycemia risk. Reduced intake, acute illness, kidney dysfunction, and other factors can alter risk as well.
At the beta cell, incretin receptors couple nutrient sensing to intracellular signaling, and when glucose metabolism has already raised the cell's readiness to secrete insulin, cyclic AMP pathways amplify exocytosis of insulin-containing granules. Incretin signaling therefore strengthens a glucose-triggered process rather than replacing it, which is also why the presence of a receptor does not guarantee a normal effect: beta-cell health, receptor signaling, glucose toxicity, lipotoxicity, neural input, and the surrounding metabolic state all influence the response you actually measure.
GLP-1 does more than stimulate insulin#
GLP-1 can suppress glucagon when glucose is elevated. Lower glucagon reduces a signal that otherwise promotes hepatic glucose production. The glucagon response is context-sensitive: protection against hypoglycemia should not be described as a simple, permanent shutdown of alpha cells.
GLP-1 also slows gastric emptying, especially during early treatment and with shorter-acting receptor agonism. Slower delivery of nutrients from the stomach can blunt and delay a post-meal glucose peak. The magnitude varies, and tachyphylaxis can reduce this effect with sustained signaling.
Signals in the gut and brain contribute to earlier satiation and lower energy intake in many people; these effects help explain weight loss with some GLP-1 receptor agonists, but your own response may differ from the average. Nausea is an adverse effect, not the desired mechanism or proof that a medicine is working.
GLP-1 biology also includes cardiovascular, renal, inflammatory, and neural questions, but clinical outcome benefits demonstrated for particular medicines and populations cannot automatically be assigned to every molecule or inferred from a receptor diagram. Outcome trials, not mechanism alone, establish outcome claims.
GIP is not merely a weaker GLP-1#
GIP strongly amplifies glucose-stimulated insulin secretion in normal physiology. In established type 2 diabetes, the insulin response to physiologic or infused GIP is often markedly reduced, and by contrast, pharmacologic GLP-1 receptor activation can still produce meaningful insulin and glucagon effects.
That contrast helped direct early drug development toward GLP-1 receptors. It did not make GIP irrelevant. GIP receptors occur in pancreatic, adipose, neural, and other tissues, and GIP actions can differ according to glucose concentration and metabolic state; combined GIP and GLP-1 receptor agonism has shown that pharmacologic co-activation can produce clinically important effects even though the native GIP response is impaired in type 2 diabetes. The apparent paradox is a reminder that normal hormone physiology, chronic disease physiology, and sustained drug-level receptor activation are three different questions, because a drug can reach concentrations, durations, receptor balances, and tissues that a brief pulse of endogenous hormone does not reproduce.
What changes in type 2 diabetes#
The incretin effect is commonly reduced in type 2 diabetes; in a classic 1986 study, 14 people with type 2 diabetes and eight matched control participants received oral glucose and matched intravenous glucose. The difference between routes was much smaller in the diabetes group.
Several mechanisms contribute. Beta cells lose glucose sensitivity and secretory capacity. The insulinotropic response to GIP is especially impaired. GLP-1 secretion findings are more variable across studies, and a reduced incretin effect should not be equated automatically with deficient hormone production. Receptor response, beta-cell state, and glucagon regulation all matter. So do disease duration, glycemic conditions, and study methods.
This distinction prevents a common error. If the measured effect is smaller, it does not follow that the gut released no incretin hormones, and an effect can fall because the receiving tissue responds less effectively even when secretion is present.
The impairment may also be partly consequence rather than a single initiating cause. Hyperglycemia itself can worsen beta-cell responsiveness. Improved glycemia can restore some responsiveness, though it does not erase the broader disease process.
From physiology to drug classes#
Three medicine concepts are often grouped around the incretin system.
DPP-4 inhibitors slow degradation of endogenous GLP-1 and GIP. Their effect depends on the body's own hormone release and produces a more modest receptor signal than injectable receptor agonism, and they are generally weight neutral and have a low intrinsic hypoglycemia risk when not combined with medicines that cause hypoglycemia.
GLP-1 receptor agonists directly activate the GLP-1 receptor and resist rapid breakdown. Molecules differ in dosing interval, gastric-emptying effects, and efficacy. They differ in outcome evidence, adverse-effect profile, and approved indications.
Dual or multi-receptor agonists target more than one receptor, such as GIP and GLP-1 receptors, and their clinical effects are properties of a specific molecule tested at specific doses in specific populations. They should not be reduced to the sum of two endogenous hormone definitions.
Current diabetes guidance uses person-centered selection. In many adults with type 2 diabetes who need injectable glucose-lowering treatment but do not have severe hyperglycemia or a hyperglycemic crisis, GLP-1-based therapy may be preferred before insulin. Cardiovascular disease, heart failure, and chronic kidney disease can change the choice. So can weight goals, hypoglycemia risk, and adverse effects. So can cost, access, and your own preference. Severe hyperglycemia, catabolic symptoms, or suspected insulin deficiency may make insulin urgent or appropriate. So may pregnancy, acute illness, or other circumstances. No physiology article can turn that framework into personal prescribing advice.
How to read an incretin claim#
First identify the level of evidence. A cell experiment can show receptor signaling, a meal study can show acute hormone and glucose effects, a randomized trial can compare hemoglobin A1C, weight, symptoms, and adverse events, and a cardiovascular or kidney outcome trial can evaluate clinical events. Those are four different questions. A claim settled at one level is untested at the next.
Then identify the intervention precisely. Native GLP-1, a DPP-4 inhibitor, one GLP-1 receptor agonist, and one dual agonist are not interchangeable. Molecule, dose, and comparator belong in the claim. So do duration, population, and background therapy.
Check whether the endpoint is mechanistic, intermediate, or clinical. A change in insulin concentration does not by itself prove durable glycemic benefit. A change in hemoglobin A1C does not by itself establish fewer cardiovascular events. A weight result does not describe body composition, tolerability, persistence, or what happens after discontinuation.
Finally, inspect harms and missingness. Gastrointestinal adverse effects can cause treatment discontinuation and missing outcome data. Gallbladder disease, pancreatitis warnings, and retinopathy considerations for some contexts need product-specific assessment. So do procedures requiring sedation and contraindications. Class-level shorthand is not enough for your decision.
The meal is a coordinated signal#
The incretin effect replaced a glucose-only picture with a systems view. Oral nutrients activate gut hormones, neural pathways, gastric motility, pancreatic secretion, hepatic metabolism, and brain signals in a timed sequence. GIP and GLP-1 are central messengers in that network.
The concept also teaches a broader evidence lesson. A matched-route experiment can reveal physiology, but treatment claims require drug-specific trials. Type 2 diabetes changes the response to native hormones, but pharmacology can produce a different receptor pattern. A mechanism may explain a result without guaranteeing it.
The most accurate summary is therefore modest and powerful: the route by which glucose enters the body changes the insulin response because the gut actively helps regulate metabolism.
References#
- Nauck MA, et al. Reduced incretin effect in type 2 diabetes. Diabetologia. 1986.
- Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes. Molecular and Cellular Endocrinology. 2009.
- Boer GA, Holst JJ. Incretin hormones and type 2 diabetes. Physiological Reviews. 2020.
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018.
- Feingold KR, et al. Incretin hormones. Endotext.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2026. Diabetes Care. 2026.
- U.S. Food and Drug Administration. Approval overview for the dual GIP and GLP-1 receptor agonist tirzepatide.
For your own health, talk with your clinician.*
Questions and answers
Is insulin itself an incretin hormone?
No. Insulin is produced by pancreatic beta cells. Incretin hormones are gut-derived signals that amplify insulin secretion and coordinate other parts of the meal response.
Is the incretin effect the same as the effect of a GLP-1 medicine?
No. The incretin effect is a physiologic difference between oral and matched intravenous glucose. A GLP-1 receptor agonist is a pharmacologic intervention with a longer and often stronger receptor signal.
Why is the incretin effect reduced in type 2 diabetes?
Beta-cell dysfunction, impaired GIP responsiveness, altered glucose sensing, glucagon dysregulation, chronic hyperglycemia, and disease context all contribute. Reduced effect does not necessarily mean absent hormone secretion.
Do incretin-based medicines cause hypoglycemia?
They have relatively low intrinsic risk because insulin stimulation is glucose-dependent, but risk is not zero. It rises with insulin, sulfonylureas, reduced intake, illness, and some other clinical circumstances.
Does a stronger mechanistic effect prove better long-term outcomes?
No. Mechanism can support plausibility, but comparative trials and outcome trials must establish efficacy, safety, durability, and clinical benefit for each medicine and population.